[A clinico-epidemiological study on the efficacy of thymopentin therapy in patients with chronic bronchitis and cellular immunity deficiency].
The immunological in vivo effects of thymopentin (TP5) treatment in eleven hypo-anergic patients affected with chronic bronchitis are reported. Significant improvement of cellular immunity, evaluated by skin tests, and an increase of percentage of CD4+ cells and natural killer activity are demonstrated. The clinical evaluation showed an evident reduction of infectious episodes of acute bronchitis after TP5 treatment.
Amoroso
A
A
Clinica medica III, Università La Sapienza, Roma.
Di Rosa
R
R
Guidotti
G
G
Ferri
G M
GM
Afeltra
A
A
D000368:Aged; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000150:complications* / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012882:Skin Tests; D013601:T-Lymphocytes / Q000276:immunology; D016305:Thymopentin / Q000627:therapeutic use*
D016305:Thymopentin
Studio clinico-immunologico a medio termine sull'efficacia della terapia con timopentina in pazienti affetti da bronchite cronica e deficit dell'immunità cellulare.